Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Equities

Harrow, Inc. Q2 2024 Earnings Highlights: Record Revenue and Strong Product Performance

by Team Lumida
August 10, 2024
in Equities
Reading Time: 8 mins read
A A
0
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Harrow, Inc. achieved record quarterly revenue of $48.9 million, marking a 46% increase year-over-year and a 42% increase quarter-over-quarter, with strong performance across all business segments.

Summary

Harrow’s Q2 2024 performance was driven by significant growth in branded revenue, which now surpasses compounded revenue. The company’s key products, IHEEZO and VEVYE, showed strong market traction, while the Anterior Segment business grew by over 40% compared to Q1. CEO Mark Baum expressed confidence in exceeding the $180 million revenue target for 2024, stating:

“Based on our overall operational momentum, we expect revenue in the back half of 2024 to outpace revenue in the first half of this year, and that’s especially true with TRIESENCE relaunched later this year.”

Main Themes

  • Guidance: 2024 revenue expected to exceed $180 million, excluding TRIESENCE contribution
  • New Product Performance: IHEEZO and VEVYE showing strong market adoption and growth
  • Market Expansion: Increasing market access and coverage for VEVYE
  • Product Relaunch: TRIESENCE on track for relaunch in Q4 2024
  • Sales Force Expansion: Plans to increase VEVYE salesforce coverage

Insights

  • IHEEZO quarterly unit volumes nearly doubled, up 98% from the previous quarter
  • 24 supply agreements signed with strategic retina practice accounts in 2024, including the largest retina practice group in the US
  • VEVYE prescriptions increased 212% in Q2 2024 compared to Q1, with strong refill rates
  • Anterior Segment business grew over 40% quarter-over-quarter

Market Opportunity

Harrow is targeting multiple segments within the ophthalmic market:

  1. Retina market: IHEEZO addressable opportunity estimated at over 10 million units per year
  2. Dry eye disease: More than 9 million patients suffering from moderate to severe dry eye disease
  3. Anterior segment: Stabilized and growing portfolio of acquired products

The company is expanding its salesforce to capture a larger share of these markets, particularly for VEVYE.

Market Commentary

The ophthalmic pharmaceutical market is showing strong demand for innovative products. IHEEZO is gaining traction in surgical cases, laser interventions, glaucoma surgeries, and intravitreal injections. The dry eye disease market lacks effective treatments, creating a significant opportunity for VEVYE. The relaunch of TRIESENCE is highly anticipated by retina specialists, indicating pent-up demand in the market.

Customer Behaviors

Customers are responding positively to Harrow’s products:

  • IHEEZO: 87% reorder rate among current users
  • VEVYE: Strong refill rates, indicating high patient satisfaction and treatment adherence
  • TRIESENCE: High anticipation from retina specialists for the product’s return to market

Physicians are providing positive feedback on VEVYE’s quick action, longer durability, and high tolerability.

Regulatory Policy

Harrow is actively working on market access and coverage for its products:

  • VEVYE: 166 million covered lives, 58% commercial coverage, 80% Medicaid coverage (expected to reach 100% by Q3)
  • Medicare coverage for VEVYE expected in the first quarter of 2025

Industry Insights

  • The ophthalmic market is receptive to innovative products that address unmet needs
  • Strategic agreements with large practice groups are crucial for market penetration
  • Market access and coverage play a significant role in product adoption and success
  • There is a growing demand for preservative-free, affordable ophthalmic medications

Key Metrics

Financial Metrics:

  • Q2 2024 Revenue: $48.9 million (46% YoY increase, 42% QoQ increase)
  • Branded revenue now exceeds compounded revenue

KPIs:

  • IHEEZO: 98% QoQ increase in unit volumes
  • VEVYE: 212% QoQ increase in total prescriptions
  • VEVYE: ~3,000 prescribers and growing daily
  • Anterior Segment business: 40%+ QoQ growth

Competitive Differentiators

  1. Diverse product portfolio addressing multiple ophthalmic segments
  2. Strong market access and coverage strategy for key products
  3. Ability to acquire and revitalize underperforming products
  4. Focus on preservative-free, affordable medications
  5. Strong relationships with key opinion leaders in ophthalmology

Key Risks

  1. Execution risk in expanding salesforce and market coverage
  2. Potential delays in TRIESENCE relaunch
  3. Competitive pressure in the dry eye disease market
  4. Dependence on successful integration of acquired products
  5. Regulatory risks associated with market access and pricing strategies

Analyst Q&A Focus Areas

  1. VEVYE market access and pricing strategy
  2. IHEEZO supply agreements and market penetration
  3. TRIESENCE relaunch timeline and market expectations
  4. Expansion plans for the sales organization
  5. Potential for future acquisitions and product additions

Harrow, Inc. Summary:

Harrow is positioned for strong growth in the ophthalmic pharmaceutical market, driven by the success of IHEEZO and VEVYE, the anticipated relaunch of TRIESENCE, and the stabilization of its Anterior Segment business. The company’s focus on strategic agreements, market access, and salesforce expansion should support continued revenue growth. Investors should watch for the successful relaunch of TRIESENCE, expansion of Medicare coverage for VEVYE, and the company’s ability to maintain its growth trajectory while integrating new products and expanding its market presence.

Tags: EARNINGSHARROW
Previous Post

Astrana Health Q2 2024 Earnings Highlights: Strong Growth and Strategic Expansion

Next Post

Bumble Inc. Q2 2024 Earnings Highlights: Strategic Reset Amid Growth Challenges

Recommended For You

Costco Mitigates Tariff Impact Through Strategic Sourcing and Order Advancements

by Team Lumida
2 days ago
Costco Mitigates Tariff Impact Through Strategic Sourcing and Order Advancements

Key Takeaways: Powered by lumidawealth.com Costco is reducing tariff exposure by pulling orders forward and shifting private-label product sourcing to regions where they are sold, helping to control costs...

Read more

Salesforce Raises Full-Year Sales Outlook as AI Drives Growth

by Team Lumida
3 days ago
Salesforce Raises Full-Year Sales Outlook as AI Drives Growth

Key Takeaways: Powered by lumidawealth.com Salesforce’s Q1 revenue rose 8% year-over-year to $9.83 billion, beating Wall Street expectations of $9.75 billion. Adjusted earnings per share were $2.58, exceeding the...

Read more

Global Markets Mixed as Investors Await Nvidia Earnings and Monitor Rising Bond Yields

by Team Lumida
4 days ago
Global Markets Mixed as Investors Await Nvidia Earnings and Monitor Rising Bond Yields

Key Takeaways: Powered by lumidawealth.com U.S. stock futures pointed to a slightly weaker open, with the S&P 500 futures down 0.1% and Nasdaq futures flat ahead of Nvidia’s earnings...

Read more

Markets Hold $7 Trillion in Cash Ahead of Nvidia Earnings, Eyeing AI Demand

by Team Lumida
5 days ago
Nvidia CEO Reveals Secrets Behind AI Domination Amidst Fierce Competition

Key Takeaways: Powered by lumidawealth.com Investors have $7 trillion parked in cash funds, creating significant potential for a rally if Nvidia’s earnings report meets or exceeds expectations. Institutional exposure...

Read more

Cisco Raises Revenue Outlook After Posting Strong Q3 Results Driven by AI and Networking Demand

by Team Lumida
2 weeks ago
Cisco Raises Revenue Outlook After Posting Strong Q3 Results Driven by AI and Networking Demand

Key Takeaways: Powered by lumidawealth.com Cisco Systems increased its fiscal year revenue forecast to $56.5 billion–$56.7 billion, up from $56 billion–$56.5 billion, surpassing analyst expectations of $56.4 billion. Fiscal...

Read more

Siemens Exceeds Expectations with Strong Industrial Growth, Revenue Up 7%

by Team Lumida
2 weeks ago
Siemens Exceeds Expectations with Strong Industrial Growth, Revenue Up 7%

Key Takeaways: Powered by lumidawealth.com Siemens reported a 7% revenue increase to €19.76 billion for Q2, beating analyst expectations of €19.22 billion. Net profit rose to €2.25 billion, surpassing...

Read more

Sony Projects 13% Profit Decline Amid U.S. Tariff Impact Despite Strong Quarterly Earnings

by Team Lumida
3 weeks ago
black nikon dslr camera lens

Key Takeaways: Powered by lumidawealth.com Sony’s fourth-quarter net profit rose 4.6% year-over-year to ¥197.73 billion ($1.34 billion), beating analyst expectations, driven by strong performance in its music and movie...

Read more

TSMC April Sales Surge 48% as Firms Rush to Beat U.S. Tariffs

by Team Lumida
3 weeks ago
Taiwan Exports Surge 23.5% in June: AI Demand Fuels Massive Growth

Key Takeaways: Powered by lumidawealth.com Taiwan Semiconductor Manufacturing Co. (TSMC) reported a 48% year-over-year revenue increase in April, reaching NT$349.6 billion ($11.6 billion), surpassing analysts’ expectations of a 38%...

Read more

Puma’s Earnings Meet Estimates Amid Leadership Transition and Trade Uncertainty

by Team Lumida
3 weeks ago
white nike air force 1 low

Key Takeaways: Powered by lumidawealth.com Puma reported Q1 adjusted earnings of €76 million ($86 million) before interest and taxes, slightly ahead of analyst estimates but down from the previous...

Read more

Uber Swings to Profit in Q1 Amid Bookings Growth but Misses Revenue Estimates

by Team Lumida
3 weeks ago
man with Uber eats backpack

Key Takeaways: Powered by lumidawealth.com Uber reported a Q1 profit of $1.78 billion (83 cents per share), reversing a loss of $654 million (32 cents per share) from the...

Read more
Next Post

Bumble Inc. Q2 2024 Earnings Highlights: Strategic Reset Amid Growth Challenges

Eli Lilly Q2 2024 Earnings Highlights: Exceptional Growth Driven by New Products

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

China ETFs Outshine Active Funds with 40% Annual Rise

China’s Stimulus Fuels Growth Upgrades, but Trade Risks and Structural Challenges Persist

March 26, 2025
brown metal tower

Cheniere Energy Rides Gas Price Surge: Major Buyback Plan Unveiled

August 16, 2024
person holding white round ornament

FDA Advisers Back Eli Lilly’s Groundbreaking Alzheimer’s Drug

June 12, 2024

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018